Mark Layton

Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine

Edward Keystone, Millie M Wang, Mark Layton et al. · Annals of the Rheumatic Diseases · 2012 · 310 citations

Medicine, Pharmacology, Pharmacotherapy +12

Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin

JW Janssen, Michael Buschle, Mark Layton et al. · Blood · 1989 · 307 citations · Full text

Life Sciences, Cell Biology, Hematology +13

Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes

John F. Lyons, JW Janssen, CR Bartram et al. · Blood · 1988 · 121 citations · Full text

Medicine, Genetics, Oncology +14

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

Ana Rio‐Machín, Tom Vulliamy, Nele Hug et al. · Nature Communications · 2020 · 116 citations · Full text

Life Sciences, Genetics, Hematology +17

Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic‐specific rates

Matthew Hickman, B. Modell, Peter Greengross et al. · British Journal of Haematology · 1999 · 111 citations · Full text

Public Health, Hematology, Population Health Sciences +13